Sofinnova Partners
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
Latent Labs raises £40m Series A led by Radical Ventures and Sofinnova Partners to advance AI protein design
Latent Labs develops AI foundation models for generative protein design, enabling biotech and pharmaceutical teams to computationally design new antibodies, enzymes and therapeutics more efficiently.
More venture news
- 5 Feb 2026
LawhiveLawhive raises £45m Series B led by angel Mitch Rales to speed up legal services for consumers with AI
Series BLegal - 10 Feb 2026
TemTem lands £55m Series B led by Lightspeed Venture Partners to fix the energy market with transaction infrastructure
Series BEnergy - 3 Feb 2026
Artificial LabsArtificial Labs raises £33m Series B led by CommerzVentures to provide insurance markets with digital broking and underwriting
Series BFintech
